Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections

Dr Bharti Daswani

Status and phase

Completed

Phase 4

Conditions

Vaginal Infections

Treatments

Drug: ClinSupV3ER- Extended release tablet

Drug: ClinSupV3 -soft gelatin capsule

Study type

Interventional

Funder types

Other

Identifiers

NCT01697826

CTRI/2011/04/001698 (Registry Identifier)

ND1210132-34

Details and patient eligibility

About

Randomized, Parallel Group, Active Controlled Trial to compare effectiveness and tolerability of 2 different vaginal formulations containing 200mg clotrimazole and clindamycin phosphate equivalent to 100mg clindamycin for 3 days in women clinically diagnosed to have infective vaginitis.

Full description

This is a Randomized, Comparative, Prospective, Open label, Single center study to compare the 3 day treatment course of intravaginal soft gelatin capsule containing clindamycin and clotrimazole versus intravaginal ER tablets of clindamycin and clotrimazole in patients with vaginal discharge and clinical diagnosis of bacterial, trichomonal, candidal or mixed vaginitis with respect to efficacy and tolerability; and to study the in vitro drug release pattern of intravaginal soft gelatin capsule and intravaginal ER tablets containing clindamycin and clotrimazole.
The study will be conducted in B.J. Medical College & Sassoon General Hospitals, Pune. The study will be completed in 60 patients [30 patients in each group].
The primary outcome measure is absence of any clinical sign suggestive of infective vaginitis and a vaginal swab that is negative for bacterial, trichomonal or candidal vaginitis at 8th day after start of treatment [Effectiveness in inducing a remission].
The secondary outcome measures will be
1. absence of any clinical sign suggestive of infective vaginitis and
2. a vaginal swab that is negative for bacterial, trichomonal or candidal vaginitis at 29th day after start of treatment [Effectiveness in maintaining a remission] and ability to complete the 3day course without any break or experiencing intolerable side effects [Tolerability].

Enrollment

73 patients

Sex

Female

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women with symptoms of vaginal discharge and/or odor and a clinical diagnosis of vaginitis of infective origin [based on symptoms and signs on per speculum examination]
Age at least 18 years
Capable of giving written informed consent
Agree to no intercourse for 8 days from the day of start of treatment
Agree not to douche or use any intravaginal products during the study period (including tampons, medications and devices)

Exclusion criteria

Post-menopausal women
Menstruating at diagnosis
Pregnancy
Any antifungal or antibiotic use 14 days prior to enrolment
Use of oral or intravaginal antibiotics within the past 2 weeks
Immunosuppressive drug within 4 months
Presence of vaginal / vulval ulcer
Presence of any other vulval, vaginal or medical condition, including cervical neoplasia/ treatment that might confound treatment response
Inability to keep return appointments
History of hypersensitivity to clotrimazole, clindamycin or lincomycin
History of regional enteritis, ulcerative colitis or antibiotic associated colitis
Significant disease or acute illness that in the Investigators assessment could complicate the evaluation
Intrauterine Device